Keros Therapeutics, Inc. (KROS)
11.90
-0.05
(-0.42%)
USD |
NASDAQ |
Oct 12, 10:17
Keros Therapeutics Price to Book Value : 0.8994 for Oct. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 0.9032 |
| October 08, 2026 | 0.8798 |
| October 07, 2026 | 0.8473 |
| October 06, 2026 | 0.8322 |
| October 05, 2026 | 0.8707 |
| October 02, 2026 | 0.8586 |
| October 01, 2026 | 0.8511 |
| September 30, 2026 | 0.8617 |
| September 29, 2026 | 0.8458 |
| September 28, 2026 | 0.8526 |
| September 25, 2026 | 0.8783 |
| September 24, 2026 | 0.873 |
| September 23, 2026 | 0.879 |
| September 22, 2026 | 0.8866 |
| September 21, 2026 | 0.8677 |
| September 18, 2026 | 0.8458 |
| September 17, 2026 | 0.8586 |
| September 16, 2026 | 0.8118 |
| September 15, 2026 | 0.8443 |
| September 14, 2026 | 0.8473 |
| September 11, 2026 | 0.8375 |
| September 10, 2026 | 0.8443 |
| September 09, 2026 | 0.8549 |
| September 08, 2026 | 0.8443 |
| September 04, 2026 | 0.8556 |
| Date | Value |
|---|---|
| September 03, 2026 | 0.8397 |
| September 02, 2026 | 0.8488 |
| September 01, 2026 | 0.8367 |
| August 31, 2026 | 0.8375 |
| August 28, 2026 | 0.8337 |
| August 27, 2026 | 0.8488 |
| August 26, 2026 | 0.8405 |
| August 25, 2026 | 0.8828 |
| August 24, 2026 | 0.8148 |
| August 21, 2026 | 0.8337 |
| August 20, 2026 | 0.8276 |
| August 19, 2026 | 0.839 |
| August 18, 2026 | 0.8019 |
| August 17, 2026 | 0.7921 |
| August 14, 2026 | 0.7634 |
| August 13, 2026 | 0.8057 |
| August 12, 2026 | 0.8465 |
| August 11, 2026 | 0.8042 |
| August 10, 2026 | 0.808 |
| August 07, 2026 | 0.8428 |
| August 06, 2026 | 0.805 |
| August 05, 2026 | 0.7555 |
| August 04, 2026 | 0.7747 |
| August 03, 2026 | 0.7642 |
| July 31, 2026 | 0.7611 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Incyte Corp. | 3.581 |
| Viking Therapeutics, Inc. | 8.111 |
| ACADIA Pharmaceuticals, Inc. | 2.593 |
| Alnylam Pharmaceuticals, Inc. | 22.79 |
| Anika Therapeutics, Inc. | 1.899 |
Price to Book Value Related Metrics
| PS Ratio | 21.25 |
| Price | 11.90 |
| Earnings Yield | -31.09% |
| Market Cap | 235.94M |